BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 16179727)

  • 1. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes.
    Farese RV; Sajan MP; Standaert ML
    Exp Biol Med (Maywood); 2005 Oct; 230(9):593-605. PubMed ID: 16179727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance.
    Sajan MP; Standaert ML; Rivas J; Miura A; Kanoh Y; Soto J; Taniguchi CM; Kahn CR; Farese RV
    Diabetologia; 2009 Jun; 52(6):1197-207. PubMed ID: 19357831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
    Beeson M; Sajan MP; Dizon M; Grebenev D; Gomez-Daspet J; Miura A; Kanoh Y; Powe J; Bandyopadhyay G; Standaert ML; Farese RV
    Diabetes; 2003 Aug; 52(8):1926-34. PubMed ID: 12882907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle.
    Temofonte N; Sajan MP; Nimal S; Pastoor T; Fumero C; Casaubon L; Powe JL; Standaert ML; Farese RV
    Diabetologia; 2009 Jan; 52(1):60-4. PubMed ID: 18972094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects.
    Luna V; Casauban L; Sajan MP; Gomez-Daspet J; Powe JL; Miura A; Rivas J; Standaert ML; Farese RV
    Diabetologia; 2006 Feb; 49(2):375-82. PubMed ID: 16395615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver. Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high fat-induced insulin-resistant states.
    Standaert ML; Sajan MP; Miura A; Kanoh Y; Chen HC; Farese RV; Farese RV
    J Biol Chem; 2004 Jun; 279(24):24929-34. PubMed ID: 15069067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-specific differences in activation of atypical protein kinase C and protein kinase B in muscle, liver, and adipocytes of insulin receptor substrate-1 knockout mice.
    Sajan MP; Standaert ML; Miura A; Kahn CR; Farese RV
    Mol Endocrinol; 2004 Oct; 18(10):2513-21. PubMed ID: 15256535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal muscle insulin resistance in obesity-associated type 2 diabetes in monkeys is linked to a defect in insulin activation of protein kinase C-zeta/lambda/iota.
    Standaert ML; Ortmeyer HK; Sajan MP; Kanoh Y; Bandyopadhyay G; Hansen BC; Farese RV
    Diabetes; 2002 Oct; 51(10):2936-43. PubMed ID: 12351430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappaB in obesity.
    Sajan MP; Standaert ML; Nimal S; Varanasi U; Pastoor T; Mastorides S; Braun U; Leitges M; Farese RV
    J Lipid Res; 2009 Jun; 50(6):1133-45. PubMed ID: 19202134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrasting insulin dose-dependent defects in activation of atypical protein kinase C and protein kinase B/Akt in muscles of obese diabetic humans.
    Casaubon L; Sajan MP; Rivas J; Powe JL; Standaert ML; Farese RV
    Diabetologia; 2006 Dec; 49(12):3000-8. PubMed ID: 17028898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin substrates 1 and 2 are corequired for activation of atypical protein kinase C and Cbl-dependent phosphatidylinositol 3-kinase during insulin action in immortalized brown adipocytes.
    Miura A; Sajan MP; Standaert ML; Bandyopadhyay G; Kahn CR; Farese RV
    Biochemistry; 2004 Dec; 43(49):15503-9. PubMed ID: 15581362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical protein kinase C in insulin action and insulin resistance.
    Farese RV; Sajan MP; Standaert ML
    Biochem Soc Trans; 2005 Apr; 33(Pt 2):350-3. PubMed ID: 15787604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-sensitive phospholipid signaling systems and glucose transport. Update II.
    Farese RV
    Exp Biol Med (Maywood); 2001 Apr; 226(4):283-95. PubMed ID: 11368419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BMI-related progression of atypical PKC-dependent aberrations in insulin signaling through IRS-1, Akt, FoxO1 and PGC-1α in livers of obese and type 2 diabetic humans.
    Sajan MP; Ivey RA; Farese RV
    Metabolism; 2015 Nov; 64(11):1454-65. PubMed ID: 26386696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective activation of atypical protein kinase C zeta and lambda by insulin and phosphatidylinositol-3,4,5-(PO4)(3) in skeletal muscle of rats following high-fat feeding and streptozotocin-induced diabetes.
    Kanoh Y; Sajan MP; Bandyopadhyay G; Miura A; Standaert ML; Farese RV
    Endocrinology; 2003 Mar; 144(3):947-54. PubMed ID: 12586772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-ι.
    Sajan MP; Nimal S; Mastorides S; Acevedo-Duncan M; Kahn CR; Fields AP; Braun U; Leitges M; Farese RV
    Metabolism; 2012 Apr; 61(4):459-69. PubMed ID: 22225955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance.
    Sajan MP; Lee MC; Foufelle F; Sajan J; Cleland C; Farese RV
    Cell Signal; 2018 Mar; 43():62-70. PubMed ID: 29269047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 in cultured preadipocyte-derived adipocytes and myotubes of obese subjects.
    Sajan MP; Standaert ML; Miura A; Bandyopadhyay G; Vollenweider P; Franklin DM; Lea-Currie R; Farese RV
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3994-8. PubMed ID: 15292339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone, insulin treatment, and fasting correct defective activation of protein kinase C-zeta/lambda by insulin in vastus lateralis muscles and adipocytes of diabetic rats.
    Kanoh Y; Bandyopadhyay G; Sajan MP; Standaert ML; Farese RV
    Endocrinology; 2001 Apr; 142(4):1595-605. PubMed ID: 11250941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes.
    Farese RV; Sajan MP; Yang H; Li P; Mastorides S; Gower WR; Nimal S; Choi CS; Kim S; Shulman GI; Kahn CR; Braun U; Leitges M
    J Clin Invest; 2007 Aug; 117(8):2289-301. PubMed ID: 17641777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.